Wellington Management Group
CYCN icon

Wellington Management Group’s Cyclerion Therapeutics CYCN Stock Holding History

Wellington Management Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-101,960
Closed -$24.7M – 2028
2019
Q3 		$24.7M Sell
101,960
-3,414
-3% -$737K 0.01% 906
2019
Q2 		$24.1M Buy
+105,374
New +$29.8M 0.01% 962

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group's CYCN Position: Q4 2019 in Review

Wellington Management Group sold out of Cyclerion Therapeutics (CYCN) in Q4 2019, closing a stake of 101,960 shares — an estimated $24.7M sold.

Wellington Management Group first reported a position in CYCN in Q2 2019 and held it in 2 quarters. The position peaked at $24.7M in Q3 2019. 77 funds tracked by Wall St. Rank hold CYCN as of Q4 2019.

  • Wellington Management Group reported no remaining Cyclerion Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Wellington Management Group sold 101,960 Cyclerion Therapeutics shares in Q4 2019, an estimated $24.7M.
  • Wellington Management Group first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 2 quarters.
  • Wellington Management Group's Cyclerion Therapeutics position peaked at $24.7M in Q3 2019.
  • 77 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2019.

Based on Wellington Management Group's 13F filing for Q4 2019, filed 11 Feb 2020.